Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
BioNTech SE ADR (NASDAQ: BNTX) closed the day trading at $103.01 down -1.70% from the previous closing price of $104.79. In other words, the price has decreased by -$1.70 from its previous closing price. On the day, 1.41 million shares were traded. BNTX stock price reached its highest trading level at $104.84 during the session, while it also had its lowest trading level at $101.52.
Ratios:
For a better understanding of BNTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.48 and its Current Ratio is at 8.61. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 05, 2025, Reiterated its Buy rating but revised its target price to $145 from $134 previously. On May 29, 2025, Goldman started tracking the stock assigning a Neutral rating and target price of $110.
On March 13, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $145.Citigroup initiated its Buy rating on March 13, 2025, with a $145 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 15 ’25 when Medine GmbH bought 1,774,837 shares for $112.70 per share.
Tureci Ozlem bought 185,001 shares of BNTX for $20,849,613 on Aug 15 ’25. On Jun 04 ’25, another insider, Jeggle Helmut Wolfgang, who serves as the Director of the company, bought 150,000 shares for $113.10 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BNTX now has a Market Capitalization of 24763502592 and an Enterprise Value of 10996372480. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.92 while its Price-to-Book (P/B) ratio in mrq is 1.14. Its current Enterprise Value per Revenue stands at 3.82 whereas that against EBITDA is -22.273.
Stock Price History:
The Beta on a monthly basis for BNTX is 1.39, which has changed by 0.17591321 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, BNTX has reached a high of $131.49, while it has fallen to a 52-week low of $81.20. The 50-Day Moving Average of the stock is -6.15%, while the 200-Day Moving Average is calculated to be -5.12%.
Shares Statistics:
Over the past 3-months, BNTX traded about 844.10K shares per day on average, while over the past 10 days, BNTX traded about 781300 shares per day. A total of 240.40M shares are outstanding, with a floating share count of 236.74M. Insiders hold about 1.52% of the company’s shares, while institutions hold 22.02% stake in the company. Shares short for BNTX as of 1755216000 were 6315487 with a Short Ratio of 7.48, compared to 1752537600 on 6033785. Therefore, it implies a Short% of Shares Outstanding of 6315487 and a Short% of Float of 6.84.
Earnings Estimates
Currently, 15.0 analysts are dedicated to thoroughly evaluating and rating the performance of BioNTech SE ADR (BNTX) in the stock market.The consensus estimate for the next quarter is -$0.97, with high estimates of $0.6 and low estimates of -$3.51.
Analysts are recommending an EPS of between $1.59 and -$7.68 for the fiscal current year, implying an average EPS of -$4.08. EPS for the following year is -$3.77, with 20.0 analysts recommending between $1.05 and -$7.85.
Revenue Estimates
12 analysts predict $1.02B in revenue for the current quarter. It ranges from a high estimate of $2.13B to a low estimate of $542.4M. As of the current estimate, BioNTech SE ADR’s year-ago sales were $1.24BFor the next quarter, 12 analysts are estimating revenue of $944.75M. There is a high estimate of $1.15B for the next quarter, whereas the lowest estimate is $500M.
A total of 19 analysts have provided revenue estimates for BNTX’s current fiscal year. The highest revenue estimate was $4.2B, while the lowest revenue estimate was $1.73B, resulting in an average revenue estimate of $2.38B. In the same quarter a year ago, actual revenue was $2.75BBased on 18 analysts’ estimates, the company’s revenue will be $2.46B in the next fiscal year. The high estimate is $3.55B and the low estimate is $1.5B.
